Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 2, 2013, Pages 204-208

  Wright, J L ^a,b,c   Plymate, S R ^a,b   Porter, M P ^a,b   Gore, J L ^a,c   Lin, D W ^a,c   Hu, E ^b   Zeliadt, S B ^b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

biochemical recurrence; hyperglycemia; veterans' affairs

Indexed keywords

GLUCOSE; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; GLEASON SCORE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RECURRENCE RISK; RISK ASSESSMENT;

AGED; BLOOD GLUCOSE; BRACHYTHERAPY; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; OBESITY; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK;

EID: 84882456861     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.5     Document Type: Article

References (29)

1. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL et al. Prediagnostic bodymass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008; 9: 1039-1047.
2. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348: 1625-1638. (Pubitemid 36459468)
3. Andersson SO, Wolk A, Bergstrom R, Adami HO, Engholm G, Englund A et al. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 1997; 89: 385-389. (Pubitemid 27102604)
4. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007; 109: 675-684. (Pubitemid 46233228)
5. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM et al. Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer 2007; 110: 2691-2699. (Pubitemid 350250338)
6. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007; 109: 1192-1202. (Pubitemid 46435400)
7. What are the risk factors for prostate cancer? American Cancer Society, Inc. http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/prostate-cancer- riskfactors, Accessed 2012.
8. Chornokur G, Dalton K, Borysova ME, Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate 2011; 71: 985-997.
9. Osborne CK, Bolan G, Monaco ME, Lippman ME. Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci USA 1976; 73: 4536-4540. (Pubitemid 8013935)
10. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928.
11. Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, Onorato J et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemiainduced increases in macromolecular endocytosis. J Clin Invest 1998; 101: 1142-1147. (Pubitemid 28125293)
12. DeNardo DG, Andreu P, Coussens LM. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev 2010; 29: 309-316.
13. Chan JM, Latini DM, Cowan J, Duchane J, Carroll PR. History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States). Cancer Causes Control 2005; 16: 789-797. (Pubitemid 41160043)
14. Jayachandran J, Aronson WJ, Terris MK et al. Diabetes and outcomes after radical prostatectomy: are results affected by obesity and race? Results from the shared equal-access regional cancer hospital database. Cancer Epidemiol Biomarkers Prev 2010; 19: 9-17.
15. Smith MR, Bae K, Efstathiou JA, Hanks GE, Pilepich MV, Sandler HM et al. Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. J Clin Oncol 2008; 26: 4333-4339.
16. Kim HS, Presti Jr. JC, Aronson WJ, Terris MK, Kane CJ, Amling CL et al. Glycemic control and prostate cancer progression: results from the SEARCH database. Prostate 2010; 70: 1540-1546.
17. Barba M, Sperati F, Stranges S, Carlomagno C, Nasti G, Iaffaioli V et al. Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort. Ann Oncol 2011; 23: 1838-1845.
18. Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev 2002; 11: 385-391. (Pubitemid 34408218)
19. Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev 2001; 10: 937-941. (Pubitemid 32844900)
20. Maynard C, Chapko MK. Data resources in the Department of Veterans Affairs. Diabetes Care 2004; 27(Suppl 2): B22-B26. (Pubitemid 38569260)
21. Zeliadt SB, Sekaran NK, Hu EY, Slatore CC, Au DH, Backhus L et al. Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest. J Thorac Oncol 2011; 6: 1726-1732.
22. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006; 106: 581-588. (Pubitemid 43157621)
23. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007; 17: 584-590. (Pubitemid 47096709)
24. National Comprehensive Cancer Network. Prostate Cancer (Version 3.2012). Accessed Date May 2012. URL http://www.nccn.org/professionals/physician-gls/pdf/ prostate.pdf.
25. Flood A, Mai V, Pfeiffer R, Kahle L, Remaley AT, Lanza E et al. Elevated serum concentrations of insulin and glucose increase risk of recurrent colorectal adenomas. Gastroenterology 2007; 133: 1423-1429. (Pubitemid 350029750)
26. Hong SK, Lee ST, Kim SS, Min KE, Byun SS, Cho SY et al. Significance of preoperative HbA1c level in patients with diabetes mellitus and clinically localized prostate cancer. Prostate 2009; 69: 820-826.
27. Hammarsten J, Hogstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005; 41: 2887-2895. (Pubitemid 41713128)
28. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United StatesUS Department of Health and Human Services, Center for Disease Control and Prevention: Atlanta, GA, 2011.
29. Zeliadt SB, Hoffman RM, Etzioni R, Ginger VA, Lin DW. What happens after an elevated PSA test: the experience of 13 591 veterans. J Gen Intern Med 2010; 25: 1205-1210.